Total Payments
$11,002
2024 Payments
$561.73
Companies
67
Transactions
561
Medicare Patients
4,567
Medicare Billing
$619,262
Payment Breakdown by Category
Food & Beverage$10,463 (95.1%)
Consulting$335.00 (3.0%)
Education$203.99 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,463 | 557 | 95.1% |
| Consulting Fee | $335.00 | 1 | 3.0% |
| Education | $203.99 | 3 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,408 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $806.20 | 42 | $0 (2024) |
| PFIZER INC. | $680.94 | 52 | $0 (2024) |
| Merck Sharp & Dohme LLC | $596.28 | 35 | $0 (2023) |
| Incyte Corporation | $529.18 | 12 | $0 (2022) |
| Amgen Inc. | $415.99 | 27 | $0 (2023) |
| Lilly USA, LLC | $415.97 | 26 | $0 (2022) |
| Astellas Pharma US Inc | $357.50 | 18 | $0 (2022) |
| Seagen Inc. | $332.85 | 16 | $0 (2022) |
| Sirtex Medical Inc | $322.04 | 10 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $561.73 | 22 | AstraZeneca Pharmaceuticals LP ($175.26) |
| 2023 | $69.17 | 4 | RECORDATI_RARE_DISEASES_INC. ($18.72) |
| 2022 | $2,753 | 135 | Sirtex Medical Inc ($281.31) |
| 2021 | $2,317 | 129 | AstraZeneca Pharmaceuticals LP ($240.78) |
| 2020 | $3,328 | 187 | AstraZeneca Pharmaceuticals LP ($431.41) |
| 2019 | $1,637 | 83 | AstraZeneca Pharmaceuticals LP ($294.19) |
| 2018 | $335.00 | 1 | Incyte Corporation ($335.00) |
All Payment Transactions
561 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $122.95 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.36 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $20.13 | General |
| Category: Oncology | ||||||
| 11/06/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Monoclonal Antibody | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Oncology | ||||||
| 04/09/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Food and Beverage | Cash or cash equivalent | $17.69 | General |
| Category: Oncology | ||||||
| 02/20/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 02/13/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Oncology | ||||||
| 02/12/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Oncology | ||||||
| 02/07/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.44 | General |
| Category: Hematology | ||||||
| 01/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: ONCOLOGY | ||||||
| 01/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Oncology | ||||||
| 12/06/2023 | RECORDATI_RARE_DISEASES_INC. | PANHEMATIN (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: METABOLIC AGENT | ||||||
| 11/02/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 332 | 505 | $210,322 | $58,344 |
| 2022 | 23 | 1,056 | 6,232 | $246,089 | $103,946 |
| 2021 | 35 | 1,630 | 8,539 | $448,369 | $204,497 |
| 2020 | 39 | 1,549 | 10,065 | $597,257 | $252,475 |
Total Patients
4,567
Total Services
25,341
Medicare Billing
$619,262
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 240 | $90,440 | $24,889 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 88 | $46,440 | $12,689 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 53 | 53 | $31,825 | $8,885 | 27.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $23,543 | $6,529 | 27.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 26 | $7,894 | $2,507 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 27 | $5,781 | $1,638 | 28.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 19 | $4,399 | $1,208 | 27.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 21 | 3,650 | $73,000 | $23,037 | 31.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 98 | 102 | $30,352 | $16,913 | 55.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 135 | $20,250 | $13,982 | 69.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 74 | 124 | $20,041 | $10,591 | 52.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 139 | $17,401 | $9,528 | 54.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 63 | $17,010 | $7,180 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $7,912 | $4,096 | 51.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 118 | 433 | $10,392 | $3,290 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 18 | $3,810 | $2,638 | 69.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 41 | $6,355 | $2,323 | 36.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 29 | 189 | $8,505 | $2,130 | 25.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 46 | 137 | $5,275 | $1,430 | 27.1% |
| 82728 | Ferritin (blood protein) level | Office | 2022 | 54 | 93 | $4,371 | $1,254 | 28.7% |
| 84466 | Transferrin (iron binding protein) level | Office | 2022 | 53 | 94 | $3,760 | $1,186 | 31.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 113 | 364 | $4,368 | $1,077 | 24.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 28 | 52 | $1,761 | $866.59 | 49.2% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2022 | 34 | 45 | $2,475 | $671.70 | 27.1% |
| 83540 | Iron level | Office | 2022 | 53 | 94 | $2,820 | $601.83 | 21.3% |
About Dr. Ryan Devine, DO
Dr. Ryan Devine, DO is a Medical Oncology healthcare provider based in Stuart, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1568622207.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Devine, DO has received a total of $11,002 in payments from pharmaceutical and medical device companies, with $561.73 received in 2024. These payments were reported across 561 transactions from 67 companies. The most common payment nature is "Food and Beverage" ($10,463).
As a Medicare-enrolled provider, Devine has provided services to 4,567 Medicare beneficiaries, totaling 25,341 services with total Medicare billing of $619,262. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Stuart, FL
- Active Since 06/16/2008
- Last Updated 10/31/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1568622207
Products in Payments
- KEYTRUDA (Biological) $591.28
- LYNPARZA (Drug) $559.57
- OPDIVO (Biological) $444.58
- SIR-Spheres Microspheres (Device) $322.04
- CYRAMZA (Drug) $263.14
- ZEPZELCA (Drug) $244.19
- Doptelet (Drug) $232.68
- TAGRISSO (Drug) $217.69
- PADCEV (Drug) $213.11
- Enhertu (Drug) $209.59
- XTANDI (Drug) $202.73
- BOSULIF (Drug) $201.16
- CALQUENCE (Drug) $186.24
- REBLOZYL (Biological) $183.72
- NERLYNX (Drug) $178.95
- IMFINZI (Drug) $176.09
- ERLEADA (Drug) $172.45
- VENCLEXTA (Drug) $158.00
- TUKYSA (Drug) $153.31
- Udenyca (Biological) $145.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.